p53 and RB expression predict progression in T1 bladder cancer

Area of Science:

• Urology
• Oncology
• Molecular Pathology

Background:

• Minimally invasive (stage T1) bladder cancer management remains controversial due to its intermediate risk profile.
• T1 bladder cancer poses a higher risk of progression and death compared to noninvasive Ta bladder cancer.
• Identifying high-risk T1 bladder cancer patients is crucial for optimizing clinical management.

Purpose of the Study:

• To evaluate p53 and RB tumor suppressor genes as prognostic markers for disease progression in pT1 bladder cancer.
• To determine if alterations in p53 and RB protein expression correlate with increased risk of bladder cancer progression.
• To support patient stratification for tailored treatment strategies in T1 bladder cancer.

Main Methods:

• Retrospective cohort study of 45 patients with pT1 bladder cancer.
• Analysis of p53 and RB nuclear protein expression using immunostaining.
• Assessment of progression-free survival based on protein expression patterns over a median follow-up of 3.5 years.

Main Results:

• 58% of patients exhibited altered p53 expression (positive immunostaining).
• Abnormal RB protein expression (absent or strongly homogeneous staining) was associated with increased progression risk.
• Patients with normal p53 and RB expression showed no disease progression, while those with alterations in either or both proteins had significantly increased progression (P = 0.04 and P = 0.005).

Conclusions:

• p53 and RB nuclear protein status can effectively stratify T1 bladder cancer patients based on progression risk.
• Patients with normal p53 and RB expression may be managed conservatively.
• Alterations in p53 and/or RB protein expression necessitate more aggressive treatment strategies for T1 bladder cancer.